ATE435911T1 - Antisens-oligonukleotide die fähig sind die herstellung von kapillarröhrchen zu hemmen - Google Patents

Antisens-oligonukleotide die fähig sind die herstellung von kapillarröhrchen zu hemmen

Info

Publication number
ATE435911T1
ATE435911T1 AT02751246T AT02751246T ATE435911T1 AT E435911 T1 ATE435911 T1 AT E435911T1 AT 02751246 T AT02751246 T AT 02751246T AT 02751246 T AT02751246 T AT 02751246T AT E435911 T1 ATE435911 T1 AT E435911T1
Authority
AT
Austria
Prior art keywords
animals
microm
day
nucleic acid
antisense
Prior art date
Application number
AT02751246T
Other languages
German (de)
English (en)
Inventor
Salman Al-Mahmood
Original Assignee
Gene Signal Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Signal Int Sa filed Critical Gene Signal Int Sa
Application granted granted Critical
Publication of ATE435911T1 publication Critical patent/ATE435911T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
AT02751246T 2001-06-14 2002-06-14 Antisens-oligonukleotide die fähig sind die herstellung von kapillarröhrchen zu hemmen ATE435911T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107805A FR2826010B1 (fr) 2001-06-14 2001-06-14 Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires par les cellules endotheliales
PCT/FR2002/002067 WO2002103014A2 (fr) 2001-06-14 2002-06-14 Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires

Publications (1)

Publication Number Publication Date
ATE435911T1 true ATE435911T1 (de) 2009-07-15

Family

ID=8864317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751246T ATE435911T1 (de) 2001-06-14 2002-06-14 Antisens-oligonukleotide die fähig sind die herstellung von kapillarröhrchen zu hemmen

Country Status (13)

Country Link
US (3) US7417033B2 (https=)
EP (2) EP2166095A3 (https=)
JP (1) JP4153421B2 (https=)
AT (1) ATE435911T1 (https=)
AU (1) AU2002345669B9 (https=)
CA (1) CA2451874C (https=)
CY (1) CY1109464T1 (https=)
DE (1) DE60232883D1 (https=)
DK (1) DK1409672T3 (https=)
ES (1) ES2331835T3 (https=)
FR (1) FR2826010B1 (https=)
PT (1) PT1409672E (https=)
WO (1) WO2002103014A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1931993A2 (en) * 2005-09-14 2008-06-18 Medizinische Universität Wien Means and methods for diagnosing endometriosis
US8032556B1 (en) * 2008-03-07 2011-10-04 Symantec Corporation Systems and methods for user profile data delivery
US8470997B2 (en) 2009-02-05 2013-06-25 Gene Signal International Sa Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
US8580947B2 (en) 2009-02-05 2013-11-12 Gene Signal International Sa Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
EP2418279A1 (en) * 2010-08-10 2012-02-15 Gene Signal International SA Injectable pharmaceutical composition for preventing, stabilising and/or inhibiting pathological neovascularization-related conditions
EP2540828A1 (en) 2011-06-30 2013-01-02 Gene Signal International SA Composition comprising inhibitors of IRS-1 and of VEGF
JP6159720B2 (ja) 2011-06-30 2017-07-05 ジーン シグナル インターナショナル ソシエテ アノニム Ｉｒｓ−１およびｖｅｇｆの阻害剤を含む組成物
US9682144B2 (en) 2011-06-30 2017-06-20 Gene Signal International, Sa Composition comprising inhibitors of IRS-1 and of VEGF
US9359604B2 (en) * 2012-07-03 2016-06-07 Gene Signal International Sa Inhibitor of IRS-1 for treating skin disorders
US10052343B1 (en) 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide
WO2026000245A1 (zh) * 2024-06-26 2026-01-02 思合基因(北京)生物科技有限公司 一种靶向IRS-1 mRNA的寡聚核苷酸及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0572508A4 (en) * 1991-01-18 1995-03-29 Joslin Diabetes Center Inc NUCLEIC ACID ENCODING THE INSULIN RECEPTOR SUBSTRATE-1 (IRS-1), IRS-1 PROTEIN, DISEASES AND THERAPY ASSOCIATED WITH IRS-1 METABOLISM.
FR2733913B1 (fr) * 1995-05-09 1997-08-01 Sanofi Sa Sequence d'adn a titre de medicament, et compositions pharmaceutiques en contenant
US6498139B1 (en) * 1997-09-29 2002-12-24 Daiichi Pharmaceutical Co., Ltd. Remedies for diseases caused by insulin resistance
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
ES2288473T3 (es) * 1999-05-18 2008-01-16 Dnavec Research Inc. Vector de virus deficiente en el gen de la envoltura de paramyxoviridae.

Also Published As

Publication number Publication date
EP1409672A2 (fr) 2004-04-21
CA2451874A1 (fr) 2002-12-27
PT1409672E (pt) 2009-11-04
US20080293658A1 (en) 2008-11-27
EP2166095A2 (fr) 2010-03-24
CA2451874C (fr) 2013-07-30
WO2002103014A2 (fr) 2002-12-27
AU2002345669B9 (en) 2006-06-29
FR2826010B1 (fr) 2005-02-25
DK1409672T3 (da) 2009-11-09
US20040162257A1 (en) 2004-08-19
JP2004538272A (ja) 2004-12-24
US7855184B2 (en) 2010-12-21
CY1109464T1 (el) 2014-08-13
US8828959B2 (en) 2014-09-09
EP2166095A3 (fr) 2012-01-04
EP1409672B1 (fr) 2009-07-08
WO2002103014A3 (fr) 2004-02-26
AU2002345669B2 (en) 2006-02-02
JP4153421B2 (ja) 2008-09-24
US7417033B2 (en) 2008-08-26
DE60232883D1 (de) 2009-08-20
ES2331835T3 (es) 2010-01-18
US20090082292A1 (en) 2009-03-26
FR2826010A1 (fr) 2002-12-20

Similar Documents

Publication Publication Date Title
CY1109464T1 (el) Αντισυνθετικα ολιγονουκλεοτιδια ικανα να αναστειλουν την δημιουργια τριχοειδων σωληνων
Chen et al. Topical insulin application improves healing by regulating the wound inflammatory response
George et al. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats
Ashcroft et al. The effects of ageing on cutaneous wound healing in mammals
Jiang et al. N‐methyl‐D‐aspartate and TrkB receptor activation in cerebellar granule cells: an in vitro model of preconditioning to stimulate intrinsic survival pathways in neurons
EP1352061B9 (de) Verfahren zur hemmung der expression eine zielgens
EP0831848A4 (en) Method of treatment for lung diseases using antisense oligonucleotides
ATE460481T1 (de) Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
ES2061416T3 (es) Ribozimas modificadas.
DE69005352D1 (de) Antikörper enthaltende Verabreichungssysteme für biologische verhaltensändernde Stoffe.
CA2229171A1 (en) Method of modulating gene expression with reduced immunostimulatory response
EP1549767A4 (en) MODULATION OF EXPRESSION OF FORKHEAD BOX O1A
Thippeswamy et al. The roles of nitric oxide in dorsal root ganglion neurons
ES2170065T3 (es) Modulacion de la proteina quinasa c por oligonucleotidos.
Kim et al. Chemogenetic stimulation of the Gi pathway in astrocytes suppresses neuroinflammation
Maxwell et al. Glial cell line-derived neurotrophic factor promotes the development of adrenergic neurons in mouse neural crest cultures
BR112015031018B1 (pt) Composição compreendendo um tetrapeptídeo para tratamento de condições da pele
Prasad et al. An injectable self-healing anesthetic glycolipid-based oleogel with antibiofilm and diabetic wound skin repair properties
Bothwell Neurotrophin function in skin
ES2188581T3 (es) Modulacion por oligonucleotidos de la adherencia celular.
KR930702995A (ko) 세포증식 매트릭스 및 그 용도
EP1556486B1 (de) Wirksame und stabile dna-enzyme
Söderström et al. In vitro toxicity of methyl mercury: effects on nerve growth factor (NGF)-responsive neurons and on NGF synthesis in fibroblasts
Lin et al. Interleukin-12 promotes neurite outgrowth in mouse sympathetic superior cervical ganglion neurons
DE602004006509T2 (de) Zu einem für den menschlichen cd40-rezeptor codierenden cdna-bereich homologe oligoribonukleotidsequenz sowie damit zusammenhängende duplex-oligoribonukleotide, vektoren, pharmazeutische zusammensetzungen und verwendungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1409672

Country of ref document: EP